Valneva stock jumps as Pfizer invests more than €90M to support Lyme disease vaccine trial
VLA15 is the only Lyme disease vaccine candidate currently in clinical development
Pfizer has agreed to pay €90.5 million for an 8.1% stake in French vaccines company Valneva, with whom they have been collaborating on a Lyme disease vaccine candidate.
Pfizer will buy the stake in Valneva at a price of €9.49 per share, via a reserved capital increase. The move caused a sharp rise in Valneva’s share price, surging to a high of €12.69 on Wednesday.
Valneva and Pfizer also updated the terms of their collaboration and license agreement which they announced on April 30, 2020 for the Lyme disease vaccine candidate VLA15. Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.
Earlier this year, the companies announced that the multivalent protein subunit vaccine was immunogenic in adults after a three-dose series in the Phase 2 study called VLA15-221, which built on evidence from earlier studies. They also noted that the vaccine candidate was more effective in children than in adults. VLA15 is the only Lyme disease vaccine candidate currently in clinical development.
Under the revised deal, Valneva will now fund 40% of the remaining shared development costs compared to the previously agreed 30%. Pfizer will pay Valneva tiered royalties ranging from 14% to 22%. Additionally, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales.
Valneva CEO Thomas Lingelbach commented: ‘Pfizer’s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva’s vaccine expertise. This subscription agreement will contribute to our investment in the Phase 3 study while limiting the impact on our cash position.’
Kathrin U. Jansen, Senior Vice President and Head of Vaccine Research & Development at Pfizer, added: ‘As the geographic footprint of Lyme disease widens, the medical need for vaccination becomes even more imperative. We are excited to continue partnering with Valneva on the development of VLA15 and look forward to working together to progress the program with the goal of bringing forward a vaccine that could help prevent this debilitating disease.’
According to Pfizer, there are an estimated 600,000 cases of Lyme disease across North America and Europe each year. The disease spreads through bites from infected ticks and early symptoms can include joint and muscle aches, fever, headaches and fatigue.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance